Welcome to our dedicated page for Picard Medical SEC filings (Ticker: PMI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This Picard Medical, Inc. (PMI) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Picard Medical is a Delaware corporation listed on the NYSE American, and its filings describe a business conducted through SynCardia Systems, LLC, a medical technology company that manufactures and sells the SynCardia Total Artificial Heart (STAH) for patients with advanced heart failure.
Through documents such as Form S-1 registration statements and Form 8-K current reports, investors can review detailed information about Picard Medical’s operations, financing arrangements, and risk factors. The S-1 filing explains that SynCardia’s platform includes the SynCardia 50cc and 70cc total artificial hearts, external drivers, ancillary hardware, and associated surgeon and center training. It also notes that the company’s customers are major medical centers operating heart transplant and mechanical circulatory support programs and that SynCardia operates an ISO 13485–certified quality management system.
Form 8-K filings for Picard Medical include disclosures on material definitive agreements, such as senior secured notes and warrant financings, bridge financing arrangements, and related security agreements. Additional 8-Ks furnish press releases and presentation materials related to clinical and technical updates on the next-generation, fully implantable Emperor Total Artificial Heart, as well as corporate events like conference presentations and exchange bell-ringing ceremonies.
On this page, users can follow real-time updates from EDGAR and use AI-powered summaries to understand the key points in lengthy filings. Forms such as the S-1, 8-K, and any future 10-K annual reports, 10-Q quarterly reports, or proxy statements can provide insight into Picard Medical’s capital structure, governance, risk profile, and the progress of its SynCardia and Emperor total artificial heart platforms. Insider transaction reports on Form 4, when available, can also be reviewed to see changes in beneficial ownership by company insiders.
Picard Medical, Inc. reported that NYSE American has accepted its plan to regain compliance with the exchange’s continued listing standards under Sections 1003(a)(i) and (ii). Acceptance allows the company’s common stock to continue trading on NYSE American while it works toward milestones in the compliance plan.
The company had previously reported stockholders’ equity of $3.8 million as of December 31, 2025 and a stockholders’ deficit of $(1.4) million as of March 31, 2026, along with losses in three of its four most recent fiscal years ended December 31, 2025. Picard Medical has been granted a compliance period through November 8, 2027 and is subject to a maximum period of 18 months from the original noncompliance notice to regain compliance, with periodic NYSE American review.
Picard Medical, Inc. approved a 1-for-50 reverse stock split of its common stock, implemented through a Certificate of Amendment filed in Delaware after stockholders authorized a reverse split range of 1-for-15 to 1-for-50. The split becomes effective at 5:00 p.m. Eastern Time on July 31, 2026.
Beginning August 3, 2026, the shares will trade on the NYSE American on a split-adjusted basis under the symbol PMI with new CUSIP 71953R 207. Every 50 issued and outstanding shares will be combined into one share, with no fractional shares issued and any fractions rounded up. The transaction will proportionately reduce outstanding shares while leaving each holder’s ownership percentage substantially unchanged and will adjust outstanding equity awards, warrants and other convertible securities, supporting continued compliance with NYSE American continued listing standards.
Picard Medical, Inc. reported the results of its July 17, 2026 annual meeting of stockholders. A total of 102,695,935 shares of common stock were entitled to vote as of June 26, 2026. Stockholders elected directors Richard Fang, Sam Van, Joe Xiao, and George Ye for terms expiring at the 2027 annual meeting. An advisory vote to approve executive compensation passed with 56,104,172 votes for, and stockholders supported holding future advisory votes on pay every one year, with 56,309,300 votes for the one-year frequency.
Stockholders approved an amendment to the certificate of incorporation authorizing a reverse stock split of issued and outstanding common stock at a Board-selected ratio between 1-for-15 and 1-for-50, with 58,138,876 votes for the proposal. They also approved creating Class B common stock carrying 20 votes per share, with 51,739,973 votes in favor. Finally, the appointment of MaloneBailey LLP as independent registered public accounting firm for 2026 was ratified with 58,514,997 votes for.
Picard Medical, Inc. filed an amended report to replace a prior press release with a corrected version describing its 2026 annual stockholder presentation ahead of the virtual Annual Meeting on July 17, 2026. The presentation reviews recent business performance, product development, manufacturing initiatives, and proposals to be considered by stockholders.
For the first three months of 2026, the company reports an 85% year-over-year increase in revenue, driven by a 116% increase in U.S. revenue. Gross margin was 24% for this period, compared with -4% in 2025. Management highlights ongoing manufacturing optimization efforts to strengthen quality control, improve supply chain resilience, and reduce production costs.
The company also outlines progress on its next-generation Emperor platform, an electromechanical drive system intended to replace the current external pneumatic driver and ultimately support a fully implantable total artificial heart using wireless power transfer and internal control. Planned milestones include pursuit of FDA Breakthrough Device designation, continued preclinical studies, an Investigational Device Exemption submission in 2028, and the start of clinical studies in 2029, subject to discussions with the FDA.
Picard Medical, Inc. filed an amendment to update details about a recent board appointment. The company clarifies that, effective June 23, 2026, Dr. Joe Xiao joined the Board of Directors and was appointed to the Compensation Committee and the Nominating and Corporate Governance Committee.
Dr. Xiao signed the company’s standard indemnification agreement for directors and will be paid under the existing non-employee director compensation policy described in the June 15, 2026 proxy statement. The company states there are no special arrangements leading to his selection and no related-party transactions requiring disclosure.
Picard Medical, Inc. posted a pre-recorded presentation providing an overview of recent business performance, product development progress, manufacturing initiatives, and proposals for its 2026 Annual Meeting of Stockholders. The Presentation transcript is attached as Exhibit 99.1 and is incorporated by reference. The Annual Meeting is scheduled for July 17, 2026.
Picard Medical, Inc. used a pre-recorded presentation for its 2026 Annual Meeting to update stockholders on business performance, product development, and voting proposals. Management reported first-quarter revenue growth of 85% year over year and a 28% improvement in gross margin, with U.S. revenue up 116% and representing most product revenue. The company is advancing its next-generation Emperor Total Artificial Heart platform, aiming to eliminate external pneumatic drivers and support internal power, wireless control, and transcutaneous energy transfer, supported by several issued patents. The development roadmap targets an FDA Breakthrough Device submission in 2026, GLP animal studies in 2027, IDE submission in 2028, and an early feasibility U.S. clinical study in 2029. Picard detailed a capital structure with slightly more than 92 million shares outstanding and a fully diluted share count of slightly more than 118 million. Stockholders are asked to vote on six proposals, including director elections, a reverse stock split in a range of 1-for-15 to 1-for-50 to help address New York Stock Exchange listing requirements, creation of a high-vote Class B common stock with 20 votes per share, auditor ratification, and advisory votes on executive compensation and its frequency.
Picard Medical, Inc. furnished a press release and a pre-recorded presentation dated July 2, 2026 announcing the availability of a presentation in advance of its 2026 Annual Meeting of Stockholders, scheduled for July 17, 2026. The company filed the press release and presentation as Exhibit 99.1 and Exhibit 99.2 to this report.
Picard Medical, Inc. filed a current report describing a pre-recorded presentation released ahead of its 2026 virtual Annual Meeting on July 17, 2026. The presentation highlights recent business performance, including an 85% year-over-year increase in revenue and an improved gross margin of 28% from year-end 2025, driven by a 116% increase in U.S. revenue.
The company outlines manufacturing optimization initiatives and progress on its next-generation Emperor total artificial heart platform, which replaces the external pneumatic driver with an electromechanical system and has a roadmap toward a fully implantable device. Development plans include pursuit of FDA Breakthrough Device designation, an Investigational Device Exemption submission in 2028, and planned clinical study activities in 2029. The presentation also reviews proposals for director elections, capital structure changes, auditor ratification, and advisory votes on executive compensation to be considered at the Annual Meeting.
Picard Medical, Inc. reported that on June 23, 2026, Dr. Joe Xiao was appointed to its Board of Directors, with his term set to expire at the Company’s 2026 annual meeting of stockholders. He will serve on the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, giving him a broad governance role across financial oversight, executive pay and board nominations.
Dr. Xiao entered into Picard Medical’s standard indemnification agreement for directors and will be paid under the existing compensation policy for non-employee directors described in the proxy statement filed on June 15, 2026. The Company states there are no special arrangements behind his selection and no related-party transactions requiring disclosure, indicating this is a routine independent board appointment.